Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 413,693 |
|
|||||
| News | - | ||||||
| Day High | 4.4989 | Low High |
|||||
| Day Low | 4.145 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| ACELYRIN Inc | SLRN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.1386 | -3.18% | 4.2214 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.30 | 4.145 | 4.4989 | 4.18 | 4.36 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,207 | 413,693 | US$ 4.28 | US$ 1,769,660 | - | 3.91 - 29.88 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:12:15 | formt | 250 | US$ 4.2214 | USD |
ACELYRIN Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 406.88M | 97.34M | - | 0 | -381.64M | -3.92 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ACELYRIN News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLRN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.21 | 4.98 | 4.145 | 4.61 | 611,742 | 0.0114 | 0.27% |
| 1 Month | 4.67 | 4.98 | 3.91 | 4.25 | 865,842 | -0.4486 | -9.61% |
| 3 Months | 7.86 | 7.86 | 3.91 | 5.02 | 930,498 | -3.64 | -46.29% |
| 6 Months | 6.71 | 8.885 | 3.91 | 6.65 | 1,135,347 | -2.49 | -37.09% |
| 1 Year | 18.83 | 29.88 | 3.91 | 10.74 | 1,134,542 | -14.61 | -77.58% |
| 3 Years | 23.00 | 29.88 | 3.91 | 11.51 | 1,102,326 | -18.78 | -81.65% |
| 5 Years | 23.00 | 29.88 | 3.91 | 11.51 | 1,102,326 | -18.78 | -81.65% |
ACELYRIN Description
| Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California. |
